Pre-market movers generally give a good indication of companies whose stock might make dramatic jumps throughout the day. Investors are trying to capitalize on late news from yesterday after markets close by getting a jump on other investors early in the morning.
Napster Inc. (Nasdaq: NAPS) today confirmed a marketing campaign with Toshiba America information Systems Inc. Digital Products Division, that will make Napster To Go digital music available to customers who purchase Toshiba Satellite and Qosmio notebook computers in the United States.
“Working with Toshiba, which is one of the pre-eminent names in mobile computing and consumer electronics, again demonstrates Napster’s brand equity and the value we offer to subscribers,” said Napster CEO Chris Gorog in a statement. “Consumers who purchase the latest Toshiba notebooks will have instant access to digital music courtesy of the pre-installed Napster software. We’re excited to share music with them and to introduce them to Napster.”
According to the press release, the two styles of notebook computers will come pre-loaded with award winning software for one-click access straight out of the box. The company is making good strides to start Tuesday off by gaining 7 cents to $2.80 cents this morning.
ThermoGensis (Nasdaq: KOOL) announced yesterday the appointment of a new CEO and that the company has received the long awaited approval by the Federal Drug and Administration (FDA) for one of its products; the company also revised its revenue forecast for the 2007 fiscal year, slightly below analysts’ estimates.
The news didn’t fair well with investors as the stock retreated 25 cents this morning shifting the price 10 percent to $2.35 before the bell. The new CEO will be William Osgood, who joined ThermoGenesis as general manager of operations in January and was appointed president and chief financial officer in April.
“He’s viewed here as a pretty decisive leader,” said Matt Plavan, ThermoGenesis’ CFO, in a statement. “He’s certainly hit the ground running and done a good job of getting his arms around the subcontract manufacturer” that caused problems for the company last fall.”
The company predicted income for 2007 last fall to be between $20 million and $25 million, but last February the company lowered that estimate to $18 million to $22 million and yesterday revised that estimate even lower to $16.6 million to $16.9 million.
In other news this morning, The International Journal of Cancer published studies on the anti-cancer activity of Generex Biotechnology’s (Nasdaq: GNBT) Immunotherapeutic Vaccine. The company’s subsidiary, Antigen Express, is the developer of this immunotherapeutic vaccine.
“Our recent studies further establish the scientific underpinnings of the Antigen Express technology in general and for the clinical development of AE37 in particular,” said Dr. Eric von Hofe, president of Antigen Express. “Publication in the International Journal of Cancer demonstrates the thoroughness and scientific rigor that goes into the development of Antigen Express products.”
Generex is also the developer of Oral-lyn, which is oral insulin for diabetes type 1 and 2, and is administered by injection to be absorbed into the body by the lining of the inner mouth.
The company’s share price has generated 11 cents, up 7 percent, to $1.68 this morning.
Let us hear your thoughts below: